Recent Updates — LNAI

Nasdaq notified Lunai Bioworks of non-compliance with the $2,500,000 minimum stockholders’ equity requirement due to a reported deficit of $(9,024,946) for fiscal year 2026. Because the company is under mandatory Hearings Panel Monitor status, it was ineligible for a compliance period and Nasdaq staff determined to delist its securities. The Board approved voluntary withdrawal from listing and SEC registration, with trading expected to suspend on October 30, 2026, and delisting effective around November 12, 2026. Concurrently, CFO Nathen Fuentes resigned immediately, and director Douglas W. Calder stepped down. The company also terminated its ATM Sales Agreement and intends to file Form 15 to suspend SEC reporting obligations after deregistration.

On October 9, 2026, Lunai Bioworks submitted a formal request to the Nasdaq Stock Market to immediately suspend trading in its common stock. The company cites court-ordered discovery records from pending litigation against Seven Points Capital LLC that allege substantial short selling, locate deficiencies, and failures to deliver. Lunai argues these activities indicate an unfair market and seeks urgent review by Nasdaq and FINRA before a decision is made. Trading remains active as no ruling has been issued yet. The company operates in the biotechnology sector.

Lunai Bioworks, Inc. received notification from Nasdaq confirming it has regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The company satisfied the terms of previous decisions and extension letters issued on April 2, 2026, and May 12, 2026. Consequently, the company will be subject to a mandatory one-year Panel monitor. If the company falls out of compliance with the Bid Price Rule during this monitoring period, it will be ineligible for standard compliance plans or extensions, potentially leading to a delisting determination. Lunai Bioworks, Inc. is a biotechnology company.